Suvorexant’s Strike One: Higher Doses Out, More Low Dose Studies In
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s “complete response” for insomnia drug suvorexant indicates FDA wants drug doses the company has said are ineffective.